Orchestra BioMed Holdings (OBIO) Research & Development (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Research & Development for 5 consecutive years, with $15.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 17.05% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $60.5 million (up 28.21% YoY), while the FY2025 annual figure was $58.2 million, up 35.93% from the prior year.
• Research & Development eased to $15.8 million in Q1 2026 per OBIO's latest filing, from $16.8 million in the prior quarter.
• Across five years, Research & Development topped out at $16.8 million in Q4 2025 and bottomed at $3.5 million in Q1 2022.
• Historically, Research & Development has averaged $10.1 million across 5 years, with a median of $9.1 million in 2024.
• Annual changes were most pronounced in 2023 — Research & Development surged 137.59% — and 2024, when it gained 10.39%.
• Orchestra BioMed Holdings' Research & Development stood at $7.5 million in 2022, then advanced by 12.83% to $8.5 million in 2023, then advanced by 28.9% to $11.0 million in 2024, then jumped by 53.34% to $16.8 million in 2025, then fell by 6.19% to $15.8 million in 2026.
• Business Quant data shows OBIO's Research & Development at $15.8 million in Q1 2026, $16.8 million in Q4 2025, and $14.0 million in Q3 2025.